Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Lisa L. Wei"'
Autor:
Yong Zeng, Ryan Boyd, Joshua Bartoe, Henry E. Wiley, Dario Marangoni, Lisa L. Wei, Paul A. Sieving
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 422-427 (2020)
Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with mo
Externí odkaz:
https://doaj.org/article/81bf04d9c7754b298b561135526c4165
Autor:
Joshua T. Bartoe, Ryan F. Boyd, Lisa L. Wei, Henry E. Wiley, Paul A. Sieving, Yong Zeng, Dario Marangoni
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 422-427 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with mo
Autor:
Kazuhiro Ueyama, Keisuke Mori, Takuhei Shoji, Hidekazu Omata, Peter L Gehlbach, Douglas E Brough, Lisa L Wei, Shin Yoneya
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108071 (2014)
To evaluate localization and transgene expression from adenoviral vector of serotypes 5, 35, and 28, ± an RGD motif in the fiber following intravitreal or subretinal administration.Ocular transduction by adenoviral vector serotypes ± RGD was studie
Externí odkaz:
https://doaj.org/article/62f342e4389d46108cee1bf3616dd905
Autor:
Camasamudram Vijayasarathy, Alaknanda Mishra, Paul A. Sieving, Henry E. Wiley, Yong Zeng, H. Nida Sen, Lisa L. Wei, Catherine A Cukras
Publikováno v:
Mol Ther
Molecular therapy : the journal of the American Society of Gene Therapy, vol 29, iss 6
Molecular therapy : the journal of the American Society of Gene Therapy, vol 29, iss 6
This study explored systemic immune changes in 11 subjects with X-linked retinoschisis (XLRS) in a phase I/IIa adeno-associated virus 8 (AAV8)-RS1 gene therapy trial (ClinicalTrials.gov: NCT02317887). Immune cell proportions and serum analytes were c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f17a7c2ca754490b1aa4becd6fc55a1c
https://europepmc.org/articles/PMC8178519/
https://europepmc.org/articles/PMC8178519/
Autor:
Sten Kjellstrom, Paul A. Sieving, Lisa L. Wei, Camasamudram Vijayasarathy, Yong Zeng, H. Nida Sen, Zhijian Wu, Henry E. Wiley, Brett G. Jeffrey, Peter Colosi, J. Fraser Wright, Suja Hiriyanna, Ronald A. Bush, Catherine A Cukras, Amy Turriff, Tae Kwon Park, Dario Marangoni, Lucia Ziccardi
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy, vol 26, iss 9
This study evaluated the safety and tolerability of ocular RS1 adeno-associated virus (AAV8-RS1) gene augmentation therapy to the retina of participants with X-linked retinoschisis (XLRS). XLRS is a monogenic trait affecting only males, caused by mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a34bfd5a5f87ac28292b0bda77fd24
https://hdl.handle.net/11368/3002667
https://hdl.handle.net/11368/3002667
Autor:
Lisa L. Wei, Dario Marangoni, Ronald A. Bush, Peter Colosi, Zhijian Wu, Paul A. Sieving, Suja Hiriyanna, Yong Zeng, Henry E. Wiley, Caroline J. Zeiss, Camasamudram Vijayasarathy
Publikováno v:
Human gene therapy. Clinical development, vol 25, iss 4
X-linked retinoschisis (XLRS) is a retinal disease caused by mutations in the gene encoding the protein retinoschisin (RS1) and one of the most common causes of macular degeneration in young men. Currently, no FDA-approved treatments are available fo
Autor:
Joshua T. Bartoe, Lucia Ziccardi, Zhijian Wu, Camasamudram Vijayasarathy, Paul A. Sieving, Kiran Palyada, Lisa L. Wei, Dario Marangoni, Ronald A. Bush, Maria José Santos, Suja Hiriyanna, Peter Colosi, Yong Zeng
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
X-linked retinoschisis (XLRS) is a retinal disease caused by mutations in the gene encoding the protein retinoschisin (RS1) and is one of the most common causes of macular degeneration in young men. Our therapeutic approach for XLRS is based on the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8d897a15a3e19c66924038e40f42c4b
https://hdl.handle.net/11368/3002696
https://hdl.handle.net/11368/3002696
Autor:
Robert N. Frank, Syed Mahmood Shah, Quan Dong Nguyen, Robert DiBartolomeo, Michael L. Klein, Jennifer Macko, Peter A. Campochiaro, David A. Saperstein, Anurag Gupta, Lisa L. Wei, Eric R. Holz, J. Timothy Stout
Publikováno v:
Human Gene Therapy. 17:167-176
Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium- derived factor (AdPEDF.11). D
Publikováno v:
Plastic and Reconstructive Surgery. 115:1871-1876
Background: Lacrimal drainage dysfunction is a common and problematic consequence of any pathologic process that interferes with the physiology or continuity of the lacrimal drainage apparatus. The literature widely documents several reliable, safe,
Autor:
Douglas E. Brough, H. Omata, Shin Yoneya, Takuhei Shoji, Lisa L. Wei, Peter L. Gehlbach, Keisuke Mori, Kazuhiro Ueyama
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108071 (2014)
PLoS ONE
PLoS ONE
Purpose To evaluate localization and transgene expression from adenoviral vector of serotypes 5, 35, and 28, ± an RGD motif in the fiber following intravitreal or subretinal administration. Methods Ocular transduction by adenoviral vector serotypes